PROTECTION trial - visual abstract

Should We Protect Kidney Function with Intravenous Amino Acids? Checkout the colorful VA of PROTECTION Trial by NSMC Intern Samantha Verdugo .

View fullsize

NephJC Rewind: PATH-BP

We have been doing NephJC for over ten years and we feel, in that time we have covered the most important manuscripts in nephrology. With a decade of history NephJC has covered a large amount of the clinical evidence used in day to day clinical care. In fact I find myself sending links to old NephJC summaries pretty commonly and we would like to surface some of these older summaries from time to time. So here is out first NephJC Rewind

Last week JAMA Internal Medicine published this manuscript any Tim Anderson, Management of Elevated Blood Pressure in the Hospital—Rethinking Current Practice. Here, Dr. Anderson is trying to operationalize the work he has been doing for quite some time demonstrating the lack of efficacy and frank harm caused by treating inpatient hypertension. This has been explored in NephJC, Freely Filtered, and NephMadness. As part of this manuscript he supplied a flow chart that showed acetaminophen as a cause of hypertension:

I tweeted about this and a number of people asked about acetaminophen being listed as a cause of drug induced hypertension. This is where PATH-BP comes in (MacIntyre, Circulation 2022). This was a well done cross over trial with a two week washout. Patients took a gram of acetaminophen four times a day or a matched placebo.

The primary outcome was a change in mean daytime systolic ambulatory BP.

There was a statistically significant increase in mean daytime systolic ambulatory BP of 4.7 mm Hg (95% CI, 2.9-6.6; P<0.0001) with acetaminophen compared with placebo.

This was not a mechanistic study so we don’t no why but it is possible that acetaminophen blocks renal prostaglandin synthesis just like NSAIDs do.

Take a look at NephJC’s discussion as well as the original paper.

Estudio RADAR - El Resumen Visual

El Resumen Visual

¿Realmente existen diferencias entre los pacientes con enfermedades renales raras de otras causas de ERC?

Veamos este resumen visual creado por el miembro de la facultad NephEdC, Brian Rifkin, el cual activa el RaDaR hacia las enfermedades renales raras.

The RADAR study - Visual Abstract

Are patients with rare kidney diseases different from other CKD? Check out the beautiful VAs by NSMC faculty Brian Rifkin and Cristina Popa

View fullsize

View fullsize

Post hoc del estudio COMPASS _ El Resumen Visual

El Resumen Visual

¿Cuál es el riesgo de desarrollar enfermedad renal con el uso de inhibidores de la bomba de protones?

Observemos este resumen visual creado por la pasante de NephEdC, Rowan Zyada, del análisis post-hoc en el estudio COMPASS el cual trata de reflejar el riesgo asociado entre el uso de IBP y la incidencia de enfermedad renal.

COMPASS Trial post hoc analysis - The Visual Abstract

Are proton pump inhibitors detrimental to kidney function?

Checkout the visual abstract for the post hoc observational analysis from the COMPASS Trial by NSMC Intern Rowan Zyada!

View fullsize

FLOW - El Resumen Visual

¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!

Del monstruo de Gila al estudio FLOW.

Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.

View fullsize

FLOW- the Visual Abstract

‘FLOW’ing with the Semaglu’TIDE’!

Check the beautiful visual abstract made by NephEdC intern Anjana Gopal, with an appearance of the Gila monster as well.

View fullsize

KDIGO 2024 CKD guidelines part 2 - Visual Abstract

Checkout the top 10 takeaways by KDIGO on the management of people with CKD. VA by Dr Vamsidhar Veeranki

KDIGO CKD GUIDELINES - VISUAL ABSTRACT

Check out the TOP 10 takeaways from KDIGO - CKD guidelines on evaluation of people with or at risk of CKD by NSMC Intern Stephanie Torres

View fullsize